Descripción

Baseline characteristics or initial outcome data from the randomized placebo-controlled trial evaluating Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 for IBS symptom relief in 251 adults.

Figure 2

Chart

Source Paper

Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in Alleviating Symptoms of Irritable Bowel Syndrome (IBS): A Randomized, Placebo-Controlled …

Nutrients (2020)

PMID: 32326347

DOI: 10.3390/nu12041159

Cite This Figure

![Figure 2: Baseline characteristics or initial outcome data from the randomized placebo-controlled trial evaluating Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 for IBS symptom relief in 251 adults.]()

> Source: Erin D Lewis et al. "Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in A." *Nutrients*, 2020. PMID: [32326347](https://pubmed.ncbi.nlm.nih.gov/32326347/)

<figure>
  <img src="" alt="Baseline characteristics or initial outcome data from the randomized placebo-controlled trial evaluating Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 for IBS symptom relief in 251 adults." />
  <figcaption>Figure 2. Baseline characteristics or initial outcome data from the randomized placebo-controlled trial evaluating Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 for IBS symptom relief in 251 adults.<br>  Source: Erin D Lewis et al. "Efficacy of Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175 in A." <em>Nutrients</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32326347/">32326347</a></figcaption>
</figure>

Evidencia relacionada

Bifidobacterium longum para Irritable Bowel Syndrome (IBS)

Calificación B · 4 estudios